Literature DB >> 2510080

Haemodialysis efficiency after long-term treatment with recombinant human erythropoietin.

S Casati1, M Campise, M Crepaldi, J Lobo, G Graziani, C Ponticelli.   

Abstract

In 11 chronic haemodialysis patients we investigated whether the increase in haematocrit during recombinant human erythropoietin (rHuEPO) treatment might alter the long-term efficiency of haemodialysis. After correction of anaemia with rHuEPO (mean Ht 35 +/- 2% vs 19 +/- 2% at baseline) (p 0.001), mean predialysis creatinine and urea did not change, while predialysis phosphate (1.77 +/- 0.38 vs 1.51 +/- 0.29 mmol/l) were significantly increased (p 0.01). In six of the 11 rHuEPO treated patients a post- versus pre-dialysis haemoconcentration (haematocrit 44% vs 35%) not attributable to different ultrafiltration regimes, was observed. In these 6 patients mean predialysis phosphate, creatinine and urea tended to be higher, but not significantly, in comparison to he remaining 5 patients who did not haemoconcentrate. Dialyser clearances and total extractions for urea, creatinine, phosphate and inulin were compared to those of 11 matched haemodialysis patients with anaemia. No differences were observed either for small and middle molecule clearances or their extractions between rHuEPO and anaemic patients. In conclusion, dialysis efficiency is not affected if haematocrit values are kept about 35%.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510080     DOI: 10.1093/ndt/4.8.718

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  2 in total

1.  A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries.

Authors:  B Leese; J Hutton; A Maynard
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

2.  Alterations of erythrocyte rheology and cellular susceptibility in end stage renal disease: Effects of peritoneal dialysis.

Authors:  Nesrin Zeynep Ertan; Semra Bozfakioglu; Elif Ugurel; Mukaddes Sinan; Ozlem Yalcin
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.